Merck rises after cholesterol drug trial data
View all comments(0)
Shares of drugmaker Merck MRK.N rise 1.7% to $80.26 premarket
Co says its oral drug, enlicitide decanoate, met the main goals of lowering bad cholesterol in two late-stage trials
Enlicitide demonstrated significant reductions in low-density lipoprotein cholesterol compared to placebo in patients with high cholesterol
The drug also outperformed other oral non-statin therapies in patients already taking statins, a common type of cholesterol-lowering medication, co says
Enlicitide works by inhibiting a type of protein, PCSK9, which plays a key role in regulating cholesterol levels in the blood
As of last close, stock down 20.6% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.